dc.creatorBrance, María Lorena
dc.creatorBrun, Lucas Ricardo Martín
dc.creatorDi Loreto, Verónica Elina
dc.creatorLupo, Maela
dc.creatorRigalli, Alfredo
dc.date.accessioned2017-12-12T14:40:36Z
dc.date.available2017-12-12T14:40:36Z
dc.date.created2017-12-12T14:40:36Z
dc.date.issued2014-08
dc.identifierBrance, María Lorena; Brun, Lucas Ricardo Martín; Di Loreto, Verónica Elina; Lupo, Maela; Rigalli, Alfredo; Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats; Taylor & Francis Ltd; Climacteric; 17; 4; 8-2014; 478-485
dc.identifier1369-7137
dc.identifierhttp://hdl.handle.net/11336/30250
dc.identifier1473-0804
dc.identifierCONICET Digital
dc.identifierCONICET
dc.description.abstractObjective Osteoporosis is the consequence of an imbalance in bone remodeling caused by excessive resorption or inappropriate bone formation. This paper proposes a sequential treatment with monofl uorophosphate (MFP) and zoledronic acid (Z), together with changes in the calcium content in the diet. Method Seven-week-old female Sprague Dawley rats were divided into fi ve groups ( n 21 per group): (1) sham-operated rats (Sham); (2) ovariectomized (OVX) rats fed with a normal calcium diet (OVX); (3) OVX rats fed with a normal calcium diet and treated sequentially with monofl uorophosphate and zoledronic acid (OVX.G1); (4) OVX rats sequentially fed with a low calcium diet and then a high calcium diet, without treatment (OVX.G2); (5): OVX rats fed with a low calcium diet and then a high calcium diet, treated sequentially with monofl uorophosphate and zoledronic acid (OVX.G3). Results After 150 days, the OVX.G3 group showed a similar bone volume to that of the Sham group due to an increase in trabecular number. Dual X-ray absorptiometry bone analysis showed an increase of 9.8% compared with OVX rats. Additionally, an increase in the fracture load at the cortical bone and higher fracture load, ultimate load and stiffness in the compression test were found. Conclusion The sequential treatment with monofl uorophosphate and zoledronic acid increases trabecular bone mass, bone mineral density and bone strength.
dc.languageeng
dc.publisherTaylor & Francis Ltd
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3109/13697137.2013.860117
dc.relationinfo:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.3109/13697137.2013.860117
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectMonofluorophosphate
dc.subjectZoledronic Acid
dc.subjectOsteoporosis
dc.subjectBone Mass
dc.subjectBone Strength
dc.titleSequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución